Skip to main content

Table 2 Causes of omalizumab discontinuation at t − 1 and t − 2

From: Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia

Causes

t − 1 n (%)

t − 2 n (%)

Administrative barriers/health insurance company did not authorize

3 (37.5)

1 (6.67)

Adverse event

3 (37.5)

3 (20)

Worsening of symptoms/therapy change

1 (12.5)

Suspended by -pulmonologist decision (no explicit reason)

1 (12.5)

Suspended by allergologist decision (no explicit reason)

3 (20)

Distant home

2 (13.3)

Asthma exacerbation

1 (6.7)

Diagnosis and treatment of cancer

1 (6.7)

Weight gain

1 (6.7)

No response to treatment

1 (6.7)

Persistency of shortness of breath and wheezing

1 (6.7)

Improvement and the need of provocation tests

1 (6.7)